Source comparison
Comparison: Tesamorelin Fat Loss Protocol Dosage Timing vs Other GH Secretagogues
Mechanism GHRH receptor agonist. Stimulates pituitary GH release Ghrelin receptor agonist. Pulse-based GH secretion GHRH analog + ghrelin agonist. Dual pathway Ghrelin receptor agonist. Sustained GH elevation Tesamorelin targets GHRH receptors with highest spe
This comparison does not assign a generated winner or score.
- Mechanism
- GHRH receptor agonist. Stimulates pituitary GH release
- Ghrelin receptor agonist. Pulse-based GH secretion
- GHRH analog + ghrelin agonist. Dual pathway
- Ghrelin receptor agonist. Sustained GH elevation
- Tesamorelin targets GHRH receptors with highest specificity for visceral fat reduction
- Injection Timing
- Once nightly, 3–4 hours post-meal, 90 min pre-sleep
- Three times daily (morning, post-workout, pre-sleep)
- Once nightly or twice daily depending on CJC variant
- Once daily, any time (oral)
- Single nightly injection offers best compliance and aligns with natural GH rhythm
- Visceral Fat Selectivity
- High. 15–18% VAT reduction in clinical trials
- Moderate. General lipolysis, less VAT-specific
- Moderate-high. Depends on dosing frequency
- Low-moderate. Increases hunger, may offset fat loss
- Tesamorelin shows strongest clinical evidence for VAT-specific reduction
- Half-Life
- 38 minutes (modified GHRH structure)
- 2 hours
- 6–8 days (CJC-1295 DAC variant)
- 24 hours
- Short half-life requires daily dosing but avoids receptor desensitization
- Side Effect Profile
- Injection site reactions (10–15%), transient hyperglycemia (5%)
- Mild. Cortisol/prolactin elevation at high doses
- Water retention, numbness (CJC-related)
- Severe hunger, water retention, possible insulin resistance
- Tesamorelin has the most favorable tolerability in long-term use
- Cost (Monthly Supply)
- $600–900 research-grade
- $180–250 (90 doses at 250mcg)
- $220–300
- $80–120
- MK-677 is cheapest but lacks VAT specificity; tesamorelin delivers targeted results